Ardent Health Earnings Call: Strength Today, Caution Ahead

Ardent Health Partners, Inc. ((ARDT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Ardent Health Partners’ latest earnings call struck a cautiously upbeat note, pairing record 2025 revenue, EBITDA and cash flow with a sober assessment of payer, policy and cost headwinds. Management highlighted clear operational momentum and balance-sheet strength, yet emphasized that 2026 will be a digestion year before technology and IMPACT savings are expected to restore EBITDA growth in 2027.

Record 2025 Results and Strong Cash Generation

Ardent reported full-year 2025 revenue of $6.3 billion, up 6% year over year, and adjusted EBITDA of $545 million, a 9% gain with margin expanding 20 basis points to 8.6%. Operating cash flow surged 49% to $471 million for the year, including $223 million in the fourth quarter, underscoring improved earnings quality and cash conversion.

IMPACT Program Upsized to $55 Million

The company’s IMPACT operating transformation program is now expected to contribute about $55 million to adjusted EBITDA in 2026, up from the prior $40 million target. Roughly $5 million of these savings were realized in 2025, with the remainder slated to ramp next year as initiatives mature across operations, supply chain and revenue cycle.

Labor and Staffing Costs Bend Lower

After earlier pressure, labor trends turned favorable in the fourth quarter, with salaried wages and benefits edging down 0.4% year over year and SWB per adjusted admission falling 2%. Contract labor expense dropped 26% to $17 million, now just 2.6% of SWB, while agency FTEs were reduced by about 175 in the last four months of 2025, easing margin strain.

Balance Sheet Deleveraging and Liquidity Strength

Ardent ended 2025 with approximately $710 million of cash, up about $150 million from the prior year, and total available liquidity near $1.0 billion. Lease-adjusted net leverage fell roughly half a turn to 2.5x, total net leverage stood at 0.8x, and total debt was $1.1 billion, giving the company ample flexibility to navigate industry volatility.

Operational Execution and Q4 Efficiency Gains

Fourth-quarter adjusted EBITDA came in at $134 million, roughly 2% above the midpoint of guidance, reflecting better-than-planned operations. First-case on-time starts in operating rooms improved by more than 10 percentage points from the third quarter, while surgeries were flat and adjusted admissions grew about 2% in Q4 and 2.3% for the year.

AI, Virtual Care and Wearables Drive Transformation

Management spotlighted technology and AI as key levers for future efficiency, noting that an AI scribe is now used in about 85% of patient visits and has cut physician documentation time by 35%. The company plans to expand AI-assisted virtual care to more than 2,000 patient rooms by year-end, while medical wearables in select markets have reduced mortality by up to 15% and shortened length of stay by roughly a third of a day.

Disciplined 2026 Outlook and 2027 Re-Acceleration

For 2026, Ardent guided to revenue of $6.4–$6.7 billion and adjusted EBITDA of $485–$535 million, with the midpoint implying about 3.6% revenue growth. Management expects core earnings growth near 4% plus the $55 million of IMPACT savings to largely offset known headwinds and signaled confidence that EBITDA growth should resume in 2027.

Continuing Payer Denials and Professional Fee Inflation

Payer denials remained broadly unchanged from the third quarter into the fourth, and management is not counting on a major improvement in 2026 guidance. Professional fees moderated to roughly 8% growth in Q4 from 11% in Q3 but remain elevated, and Ardent has effectively baked about $50 million of annualized headwinds into its 2026 baseline.

Exchange Enrollment Risk and Subsidy Roll-Off

The company is preparing for a roughly 20% decline in exchange enrollment following the expiration of enhanced subsidies and expects about 10%–15% of that cohort to shift into employer coverage. The remainder is modeled as self-pay with utilization about 30% lower, and management estimates this exchange dynamic could represent roughly a $35 million EBITDA headwind in 2026.

2026 EBITDA Step-Down and Earnings Base Reset

Ardent’s 2026 adjusted EBITDA midpoint of $510 million sits below the 2025 actual of $545 million, reflecting a deliberate reset of the earnings base. After annualizing about $50 million of 2025 headwinds and restoring roughly $20 million of short-term incentive compensation, management sees a jump-off base around $475 million that should support healthier growth beyond 2026.

Cash Flow Timing Headwind, Not Deterioration

Management also flagged a roughly $50 million year-over-year cash flow headwind in 2026 tied to the timing of payroll cycles rather than weakening fundamentals. Investors were reminded that this is a calendar effect, not an operational decline, and should reverse over time as payment schedules normalize.

Muted Q4 Revenue Growth and Mixed Volume Trends

Fourth-quarter revenue of $1.61 billion was essentially flat year over year but would equate to roughly 3% growth after adjusting for prior-year New Mexico DPP benefits. While surgeries were basically flat in the period, adjusted admissions posted modest 2% growth, and full-year admissions rose 5.3%, signaling steady demand despite payer and mix pressures.

Policy Wild Cards and Rural Health Fund Upside

Ardent sees potential upside from a Rural Health Fund, estimating that about a third of its hospitals could qualify, but neither timing nor magnitude is clear and no benefit was included in 2026 guidance. Broader policy shifts, including prior authorization changes and Medicaid redeterminations, remain additional sources of uncertainty that the company is monitoring closely.

2026 Guidance and Path Back to Growth

Looking ahead, management’s 2026 plan calls for 1.5%–2.5% adjusted admissions growth and maintains a cautious stance on payer denials and professional fees, which are modeled to grow at high-single-digit rates. With about $55 million of IMPACT savings, an expected $35 million exchange drag and a roughly $50 million payroll timing headwind, Ardent is framing 2026 as a transition year before EBITDA growth is expected to reaccelerate in 2027.

Ardent’s earnings call painted the picture of a company executing well operationally while bracing for a tougher reimbursement and policy backdrop in the near term. Record 2025 performance, improving labor metrics, strong liquidity and a growing technology advantage give management confidence that after a reset year in 2026, the business is positioned to resume EBITDA growth and create value for investors over the medium term.